Tanibirumab - PharmAbcine

Drug Profile

Tanibirumab - PharmAbcine

Alternative Names: Anti-KDR mAb - PharmAbcine; SSS-23; TTAC-0001

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAbcine
  • Developer 3SBio; PharmAbcine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Solid tumours
  • Preclinical Cancer; Choroidal neovascularisation

Most Recent Events

  • 01 Apr 2018 Tanibirumab receives Orphan Drug status for Glioblastoma in USA
  • 01 Apr 2018 PharmAbcine plans a clinical trial for Glioblastoma (Monotherapy, Second-line therapy or greater)
  • 01 Feb 2018 PharmAbcine and Merck and company plans a phase I/II trial for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top